NCT05890131View on ClinicalTrials.gov

Implementation of SGLT-2 Inhibitors in Patients With Heart Failure Through a New Digital Strategy

NAActive, not recruitingINTERVENTIONAL
Enrollment

5,996

Participants

Timeline

Start Date

May 3, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

January 31, 2027

Conditions
Heart Failure
Interventions
OTHER

Digital letter

A digital letter with evidence-based information about the newly approved heart failure therapy option, SGLT-2 inhibitors. The letter will also invite recipients to be evaluated by a heart failure specialist for potential initiation of the therapy.

Trial Locations (5)

2400

Bispebjerg-Frederiksberg Hospital, Copenhagen

2650

Amager-Hvidovre-Glostrup Hospital, Hvidovre

2900

Herlev and Gentofte University Hospital, Hellerup

3400

Nordsjællands Hospital, Hillerød

4000

Sjællands Universitetshospital - Roskilde, Roskilde

All Listed Sponsors
lead

Morten Schou

OTHER